announced plans to establish its first hub in Asia. The company will open a manufacturing facility in Singapore to support a global supply of mRNA-based vaccines and therapeutics. The facility will provide rapid-response capabilities for future pandemic threats in Southeast Asia. BioNTech plans to open a regional office in Singapore before beginning construction on its new facility.
The Singapore site will be capable of producing a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The facility will also bring highly automated and end-to-end mRNA production capabilities across drug substance, drug product and fill-and-finish.
When it is operational, the facility will have an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine. BioNTech anticipates the facility will create up to 80 jobs in Singapore when the site is complete in 2023.